인사이트
Insights From Our Experts
Articles
Digital Therapeutics: Where Technology Meets Healthcare
Digital health is growing rapidly across the world, supported by technologies that not only assist disease monitoring or prevention but can also reduce the healthcare burden. Digital technologies have improved equity of access and enabled European…
Driving Commercial Excellence for CAR-T
In this session from the 6th Annual CAR-TCR Summit, Faruk Abdullah, Head of U.S. Consulting, EVERSANA™ MANAGEMENT CONSULTING and Maria Kirsch, SVP & Head of Patient Services share insight on building the future commercialization model designed…
BLOG: Targeting the ‘Right’ Patient — How Pharmaceutical Companies Can Help Physicians Connect Patients to the Right Treatments
Posted by
Dr. Richard Stefanacci on 9월 10, 20219/10/21
Not every drug is right for every patient, but for some — or the “right” patient — treatment can provide significant clinical and financial benefits. For new therapies, identification of the right patient can be a…
How Manufacturers Can Optimize and Organize Support Services for Specialty Drugs Through a Patient Touchpoint Analysis
Currently representing almost half of the overall pharmacy benefit spend, specialty drugs are classified as being high-complexity, high-touch and high-cost medications. As healthcare providers (HCPs) and patients turn to these more expensive products to treat rare,…
Adapting Patient Access Programs to Asia
In Western markets, pharmaceutical companies have developed many approaches to patient access programs (PAPs), normally emphasizing initiatives that, while helping patients, also support pricing and reimbursement initiatives, such as: Early access programs before market authorization. Financial…
Optimizing Your Digital Marketing Spend and Field Deployment to Impact Script Adoption
In today’s competitive global market, pharmaceutical companies can’t afford to waste time or resources on strategies that don’t generate scripts or fit product and patient needs. Without data-informed, fully integrated campaigns, there’s a missed opportunity to…
Webinar: Next Generation Commercial Innovation: Moving from Promise to Practice
Posted by
Rohit Sood on 8월 31, 20218/31/21
As pharma continues to evolve, commercialization models must evolve also. In this PharmaVOICE webinar, EVERSANA’s Rohit Sood, EVP, COMPLETE Commercialization, and Resverlogix’s CEO Donald J. McCaffrey discuss why pharma companies are focusing on new commercial models…
Disrupting Healthcare from the Inside: How Incumbents Can Lead Change
The following opinion piece was written by Scott Snyder, Chief Digital Officer, for Knowledge@Wharton. Outsider attempts to reinvent healthcare have done little to move the needle despite billions invested in promising concepts like Microsoft’s HealthVault, IBM’s…
CHALLENGING TRADITION: The argument for integrated commercialization to improve operational agility
Today’s economics simply do not support building commercial capabilities from scratch, only to dismantle that infrastructure until the next need arrives. Manufacturers will spend approximately $200 million of commercialization costs over three years leading up to the…
BLOG: Medication Adherence Opportunities and Challenges
Posted by
Dr. Richard Stefanacci on 8월 20, 20218/20/21
“Drugs don’t work in patients who don’t take them.” − Former U.S. Surgeon General C. Everett Coop While it seems obvious, the amount of attention given to adherence is extremely low, especially in comparison to the high costs associated with non-adherence.…